Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.161 +0.051 (+4.60%)
Streaming Delayed Price Updated: 3:51 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss ↗
Fate Therapeutics (NASDAQ:FATE) reported mixed Q2 2025 results, beating revenue estimates with $1.9M but posting a $0.29 loss per share. Progress in autoimmune and solid tumor therapies boosted... 
Via Chartmill
News headline image
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts ↗
 
Via Benzinga
News headline image
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics ↗
 
Via Benzinga
News headline image
Where Fate Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
4 Analysts Assess Fate Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic ↗
CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus. 
Via Stocktwits
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
News headline image
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
A Preview Of Fate Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Analyst Ratings for Fate Therapeutics ↗
 
Via Benzinga
News headline image
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Recap: Fate Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock ↗
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. 
Via InvestorPlace
News headline image
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... 
Via Benzinga
Topics Stocks
News headline image
Earnings Scheduled For February 26, 2024 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.